Effect of sibutramine on plasma C-reactive protein, leptin and adiponectin concentrations: A systematic review and meta-analysis of randomized controlled trials

Antonio De Vincentis, Claudio Pedone, Umberto Vespasiani-Gentilucci, Antonio Picardi, Giuseppe Derosa, Pamela Maffioli, Amirhossein Sahebkar

Research output: Contribution to journalReview article

Abstract

Sibutramine is an anti-obesity medication whose effects on weight loss have been widely explored. Moreover, limited number of studies also evidenced its correlates on adipokines and proinflammatory markers; however, their results have not been conclusive. Hence, a systematic review and meta-analysis of available evidence was conducted in order to calculate the effect size of sibutramine therapy on C-reactive protein (CRP), leptin and adiponectin concentrations. Seven randomized clinical trials with a total of 601 subjects met the eligibility criteria. Random effect meta-analysis evidenced a significant decrease in plasma levels of CRP and leptin (weighted mean difference [WMD] -15.58%, 95% confidence interval [95%CI]: -28.84, -2.33, p=0.021 and WMD -9.25, 95%CI: -15.73, -2.78, p=0.005, respectively) and increase of adiponectin (WMD 9.86%, 95%CI: 1.76, 17.96, p=0.017) following sibutramine therapy. Subgroup analysis showed a greater CRP-lowering effect of sibutramine with doses <15 mg/day (WMD -17.26%, 95%CI: -31.02, -3.5, p=0.014) compared with doses ≥ 15 mg/day (WMD 6.01%, 95%CI: -43.38, 55.40, p=0.811). In meta-regression analysis, changes in CRP were found to be independent of baseline or percentage change in body mass index. These results suggest a significant improvement of plasma CRP, leptin and adiponectin levels following treatment with sibutramine. Possible impacts and relevance of these alterations on cardiovascular risk profile remain to be clarified, especially in post-hoc analyses of sibutramine outcome trials among people without pre-existing cardiovascular disease.

Original languageEnglish
Pages (from-to)870-878
Number of pages9
JournalCurrent Pharmaceutical Design
Volume23
Issue number6
DOIs
Publication statusPublished - Apr 1 2017

Fingerprint

sibutramine
Adiponectin
Leptin
C-Reactive Protein
Meta-Analysis
Blood Proteins
Randomized Controlled Trials
Confidence Intervals
Preexisting Condition Coverage
Adipokines
Weight Loss
Body Mass Index
Cardiovascular Diseases
Obesity
Regression Analysis

Keywords

  • Adipokines
  • Adiponectin
  • C-reactive protein
  • Leptin
  • Sibutramine

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery

Cite this

Effect of sibutramine on plasma C-reactive protein, leptin and adiponectin concentrations : A systematic review and meta-analysis of randomized controlled trials. / De Vincentis, Antonio; Pedone, Claudio; Vespasiani-Gentilucci, Umberto; Picardi, Antonio; Derosa, Giuseppe; Maffioli, Pamela; Sahebkar, Amirhossein.

In: Current Pharmaceutical Design, Vol. 23, No. 6, 01.04.2017, p. 870-878.

Research output: Contribution to journalReview article

De Vincentis, Antonio ; Pedone, Claudio ; Vespasiani-Gentilucci, Umberto ; Picardi, Antonio ; Derosa, Giuseppe ; Maffioli, Pamela ; Sahebkar, Amirhossein. / Effect of sibutramine on plasma C-reactive protein, leptin and adiponectin concentrations : A systematic review and meta-analysis of randomized controlled trials. In: Current Pharmaceutical Design. 2017 ; Vol. 23, No. 6. pp. 870-878.
@article{ec198e8ec2094d6f8bd9e05a35c5d184,
title = "Effect of sibutramine on plasma C-reactive protein, leptin and adiponectin concentrations: A systematic review and meta-analysis of randomized controlled trials",
abstract = "Sibutramine is an anti-obesity medication whose effects on weight loss have been widely explored. Moreover, limited number of studies also evidenced its correlates on adipokines and proinflammatory markers; however, their results have not been conclusive. Hence, a systematic review and meta-analysis of available evidence was conducted in order to calculate the effect size of sibutramine therapy on C-reactive protein (CRP), leptin and adiponectin concentrations. Seven randomized clinical trials with a total of 601 subjects met the eligibility criteria. Random effect meta-analysis evidenced a significant decrease in plasma levels of CRP and leptin (weighted mean difference [WMD] -15.58{\%}, 95{\%} confidence interval [95{\%}CI]: -28.84, -2.33, p=0.021 and WMD -9.25, 95{\%}CI: -15.73, -2.78, p=0.005, respectively) and increase of adiponectin (WMD 9.86{\%}, 95{\%}CI: 1.76, 17.96, p=0.017) following sibutramine therapy. Subgroup analysis showed a greater CRP-lowering effect of sibutramine with doses <15 mg/day (WMD -17.26{\%}, 95{\%}CI: -31.02, -3.5, p=0.014) compared with doses ≥ 15 mg/day (WMD 6.01{\%}, 95{\%}CI: -43.38, 55.40, p=0.811). In meta-regression analysis, changes in CRP were found to be independent of baseline or percentage change in body mass index. These results suggest a significant improvement of plasma CRP, leptin and adiponectin levels following treatment with sibutramine. Possible impacts and relevance of these alterations on cardiovascular risk profile remain to be clarified, especially in post-hoc analyses of sibutramine outcome trials among people without pre-existing cardiovascular disease.",
keywords = "Adipokines, Adiponectin, C-reactive protein, Leptin, Sibutramine",
author = "{De Vincentis}, Antonio and Claudio Pedone and Umberto Vespasiani-Gentilucci and Antonio Picardi and Giuseppe Derosa and Pamela Maffioli and Amirhossein Sahebkar",
year = "2017",
month = "4",
day = "1",
doi = "10.2174/1381612822666161006122934",
language = "English",
volume = "23",
pages = "870--878",
journal = "Current Pharmaceutical Design",
issn = "1381-6128",
publisher = "Bentham Science Publishers B.V.",
number = "6",

}

TY - JOUR

T1 - Effect of sibutramine on plasma C-reactive protein, leptin and adiponectin concentrations

T2 - A systematic review and meta-analysis of randomized controlled trials

AU - De Vincentis, Antonio

AU - Pedone, Claudio

AU - Vespasiani-Gentilucci, Umberto

AU - Picardi, Antonio

AU - Derosa, Giuseppe

AU - Maffioli, Pamela

AU - Sahebkar, Amirhossein

PY - 2017/4/1

Y1 - 2017/4/1

N2 - Sibutramine is an anti-obesity medication whose effects on weight loss have been widely explored. Moreover, limited number of studies also evidenced its correlates on adipokines and proinflammatory markers; however, their results have not been conclusive. Hence, a systematic review and meta-analysis of available evidence was conducted in order to calculate the effect size of sibutramine therapy on C-reactive protein (CRP), leptin and adiponectin concentrations. Seven randomized clinical trials with a total of 601 subjects met the eligibility criteria. Random effect meta-analysis evidenced a significant decrease in plasma levels of CRP and leptin (weighted mean difference [WMD] -15.58%, 95% confidence interval [95%CI]: -28.84, -2.33, p=0.021 and WMD -9.25, 95%CI: -15.73, -2.78, p=0.005, respectively) and increase of adiponectin (WMD 9.86%, 95%CI: 1.76, 17.96, p=0.017) following sibutramine therapy. Subgroup analysis showed a greater CRP-lowering effect of sibutramine with doses <15 mg/day (WMD -17.26%, 95%CI: -31.02, -3.5, p=0.014) compared with doses ≥ 15 mg/day (WMD 6.01%, 95%CI: -43.38, 55.40, p=0.811). In meta-regression analysis, changes in CRP were found to be independent of baseline or percentage change in body mass index. These results suggest a significant improvement of plasma CRP, leptin and adiponectin levels following treatment with sibutramine. Possible impacts and relevance of these alterations on cardiovascular risk profile remain to be clarified, especially in post-hoc analyses of sibutramine outcome trials among people without pre-existing cardiovascular disease.

AB - Sibutramine is an anti-obesity medication whose effects on weight loss have been widely explored. Moreover, limited number of studies also evidenced its correlates on adipokines and proinflammatory markers; however, their results have not been conclusive. Hence, a systematic review and meta-analysis of available evidence was conducted in order to calculate the effect size of sibutramine therapy on C-reactive protein (CRP), leptin and adiponectin concentrations. Seven randomized clinical trials with a total of 601 subjects met the eligibility criteria. Random effect meta-analysis evidenced a significant decrease in plasma levels of CRP and leptin (weighted mean difference [WMD] -15.58%, 95% confidence interval [95%CI]: -28.84, -2.33, p=0.021 and WMD -9.25, 95%CI: -15.73, -2.78, p=0.005, respectively) and increase of adiponectin (WMD 9.86%, 95%CI: 1.76, 17.96, p=0.017) following sibutramine therapy. Subgroup analysis showed a greater CRP-lowering effect of sibutramine with doses <15 mg/day (WMD -17.26%, 95%CI: -31.02, -3.5, p=0.014) compared with doses ≥ 15 mg/day (WMD 6.01%, 95%CI: -43.38, 55.40, p=0.811). In meta-regression analysis, changes in CRP were found to be independent of baseline or percentage change in body mass index. These results suggest a significant improvement of plasma CRP, leptin and adiponectin levels following treatment with sibutramine. Possible impacts and relevance of these alterations on cardiovascular risk profile remain to be clarified, especially in post-hoc analyses of sibutramine outcome trials among people without pre-existing cardiovascular disease.

KW - Adipokines

KW - Adiponectin

KW - C-reactive protein

KW - Leptin

KW - Sibutramine

UR - http://www.scopus.com/inward/record.url?scp=85017535010&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85017535010&partnerID=8YFLogxK

U2 - 10.2174/1381612822666161006122934

DO - 10.2174/1381612822666161006122934

M3 - Review article

AN - SCOPUS:85017535010

VL - 23

SP - 870

EP - 878

JO - Current Pharmaceutical Design

JF - Current Pharmaceutical Design

SN - 1381-6128

IS - 6

ER -